NEVVI Medicare utilization intelligence
or

← back

Provider profile

MANGRU, JAGINDRA MD

Rheumatology · NPI 1922028034 · CUMMING, GA

1
Groups
16
Codes · 2024
109,887
Disclosed services

MANGRU, JAGINDRA is a Rheumatology in CUMMING, GA, a member of 1 medical group, who billed 16 distinct codes to Medicare Part B in 2024.

Groups: AMERICAN ARTHRITIS AND RHEUMATOLOGY ASSOCIATES-GA, LLC (SNELLVILLE, GA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

109,887
disclosed services
16
codes billed to Medicare Part B
Prior year · CY2023 120,940 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
J1602 Injection, golimumab, 1 mg, for intravenous use
J0897 Injection, denosumab, 1 mg
J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
J1010 Injection, methylprednisolone acetate, 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96413 Administration of chemotherapy into vein, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
G2012 Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic
96415 Administration of chemotherapy into vein, each additional hour
96372 Injection of drug or substance under skin or into muscle
20610 Aspiration and/or injection of fluid from large joint

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.